Mosińska Paula, Storr Martin, Fichna Jakub
Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.
Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Therap Adv Gastroenterol. 2015 Sep;8(5):278-84. doi: 10.1177/1756283X15587866.
AST-120 (kremezin) exhibits its favourable effects in reducing the levels of renal toxins by selective adsorption of low molecular weight substances from the intestinal lumen. So far, a vast majority of studies were focused on the role of AST-120 in the treatment of chronic kidney diseases and cardiovascular disorders, and positive therapeutic effects of the agent have already been confirmed in clinical conditions. Up to the present, there are only a few studies regarding the role of AST-120 in irritable bowel syndrome (IBS). Compelling data suggest the ability of the compound to adsorb protein-bound uremic toxins and mast cell derived mediators and to modulate the farnesoid X receptor, which is a bile acid sensor indispensable for maintaining homeostasis in the intestine. In this review we focus on the actions of AST-120 on intestinal permeability, reduction of visceral sensitivity and alteration of gut motility. We also discuss whether AST-120 can mitigate common IBS symptoms, such as abdominal pain, bloating and malfunction of the colonic transit and thus improve the quality of life of patients with IBS.
AST - 120（活性炭）通过从肠腔中选择性吸附低分子量物质，在降低肾毒素水平方面显示出良好效果。到目前为止，绝大多数研究都集中在AST - 120在治疗慢性肾脏病和心血管疾病中的作用，并且该药物的积极治疗效果已在临床中得到证实。截至目前，关于AST - 120在肠易激综合征（IBS）中作用的研究仅有少数。有力数据表明该化合物能够吸附蛋白结合的尿毒症毒素和肥大细胞衍生介质，并调节法尼酯X受体，这是维持肠道内环境稳定不可或缺的胆汁酸传感器。在本综述中，我们重点关注AST - 120对肠道通透性、内脏敏感性降低和肠道动力改变的作用。我们还讨论了AST - 120是否可以减轻IBS的常见症状，如腹痛、腹胀和结肠转运功能障碍，从而改善IBS患者的生活质量。
